The Extracellular Matrix (ECM) Symposium with a focus on drug discovery and development will take place March 2021. We are celebrating 500 publications with a two half-day symposium on ECM. We will take deep dives in lung fibrosis (IPF), liver fibrosis (NASH), inflammatory bowel diseases (UC and Crohn’s), solid cancers with tissue fibrosis, inflammatory joint diseases (RA, OA, PSA), systemic sclerosis (SSC), kidney fibrosis (CKD, DKD) and heart failure (CVD) which all are diseases with dysfunctional fibroblasts and altered ECM. We are very proud to present Dr. Mina Bissell, a renowned biologist and ECM research expert, who will give a talk reflecting on the importance of the ECM. The almost-final program is attached. We are presenting the program with University of Southern Denmark (SDU), where I am an adjunct professor. We hope that many students will join. Not just from SDU but other universities, companies and people interested in the ECM. You are welcome to sign up now at ECMsymposium@nordicbio.com, and send an abstract. We will select two abstracts for oral presentations and awards. We cannot wait to host this special event. Please join us keeping the scientific buzz going in this challenging period for so many individuals. Stay safe and Happy Holidays, Prof. Morten Karsdal, CEO Nordic Bioscience
The production cycle from antibody-design to assay production is a collaboration between the research groups in RnD (and a potential sponsor) and the Antibody Research Unit (ARU) and the Technology Evaluation and Automation (TEA) group, which helps to facilitate and streamline the antibody development and assay production in RnD. There is a large degree of communication between the individual research groups and ARU and TEA to ensure the best design and development of our assays, as well as an thorough and precise final validation before the assay is transferred to our GMP production for large-scale manufacturing.
Please don't hesitate to contact us if you have any questions or other inquiries.